CULLINAN THERAPEUTICS, INC.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-53.7M | $-49.7M | $-50.6M | $-70.1M | $-48.5M | $-40.6M | $-42.0M | $-37.1M |
| Depreciation & Amortization | — | $79.0K | — | — | $76.0K | — | — | $76.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $7.6M | — | — | $9.4M | — | — | $8.2M |
| Net Cash from Operating Activities | $-38.2M | $-46.0M | $-36.9M | $-57.6M | $-43.2M | $-34.1M | $-36.3M | $-38.2M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | $0 | $0 | $0 |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $32.4M | — | — | $36.8M | — | — | $13.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $380.0K | — | — | $0 | — | — | $1.1M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | $-34.1M | $-36.3M | $-38.2M |